Élise Renaud
Canada Guide 2025
Band 3 : Investment Funds
Band 3
About
Provided by Élise Renaud
Practice Areas
Élise Renaud, partner and member of Fasken’s investment products and wealth management group, has gained valuable experience in regulations applicable to the wealth management and financial services industry. Élise recognizes the importance of this industry within Canadian society and respects the role of the Canadian Securities Administrators (CSA) and self-regulatory organizations (SRO) in protecting investors.
Élise’s practice focuses on the regulatory environment governing the daily activities of dealers, portfolio managers and investment fund managers. She advises clients during transactions outside the ordinary course of business, in particular when selling or purchasing assets under management or administration. Élise also advises portfolio managers and dealers registered under the Derivatives Act (Québec).
In addition to providing advice to registrants on registration, governance and compliance, Élise advises fund managers on creating investment funds, distributing securities of their funds and during the daily administration and management of the investment funds. She helps clients deploy diverse investment strategies aimed at retail and/or institutional investors. As such, she prepares constating and continuous disclosure documents for investment funds. She supports managers when implementing derivative-based strategies. Élise also obtains, on behalf of the registrants and investment funds she represents, exemptions from regulatory obligations.
Élise is often asked to interpret rules and guidelines issued by the CSA, the Mutual Fund Dealers Association of Canada, the Investment Industry Regulatory Organization of Canada and the Chambre de la sécurité financière.
Élise’s services are also sought by clients concerning all aspects of derivatives, including negotiations with counterparties, derivatives compliance documentation and procedures (including obligations pertaining to data reporting and central clearing of OTC derivatives).